Carmat, which has developed an artificial heart, announced fundraising for a total gross amount of 40.5 million euros.
In detail, the French MedTech obtained 36.5 million euros from specialized investors and 4.1 million euros from individuals via the PrimaryBid platform, the company said in a press release relayed by Capital.
This operation is synonymous with recovery for Carmat, which had decided on December 2, 2021 to stop implanting its Aeson artificial heart because incidents had occurred on certain prostheses.
In July 2021, an Italian patient received this heart awaiting a transplant, but two of the components of the heart prosthesis failed.
Settlements will resume
After conducting an investigation, the company was able to rectify the situation.
Here she is, ready to resume the implantations.
"The funds raised will allow us to focus calmly, over the coming months, on the resumption of the implantations of our Aeson artificial heart, scheduled for October 2022", indicated the CEO of Carmat, Stéphane Piat, quoted in the press release.
In December 2020, Carmat had obtained CE marking in Europe for its artificial heart to be used as a bridge to transplantation, or for all patients who were awaiting a transplant.
Since July 2021, the date of its first commercialization, seven Aeson cores have been implanted: five in Germany and two in Italy.
In November 2019, the results of the study of the first 11 implanted patients showed that “73% of these patients reached six months of survival with the prosthesis or a successful heart transplant”.
A success since it was the primary objective of the study.
Health
Artificial heart: Carmat has identified the origin of the "quality problem"
Health
Lille: How a 30-year-old saw three hearts pass through his body in three months
Economy
Health
carmat heart
Artificial heart
Heart